The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.102%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,960.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: "Risky" Oil Price Rally Supports Stocks

Fri, 08th Apr 2016 11:10

LONDON (Alliance News) - Oil prices were again the main driver of the London stock market midday Friday, with equities tracking the commodity higher as traders anticipated next week's meeting of oil producers to discuss a freeze in production.

"A recovery in risk appetite on Friday that has seen funds flow out of bonds and back into equities can almost exclusively be laid at the feet of a rebound in the oil price," said Jasper Lawler, market analyst at CMC Markets.

However, Lawler said Friday's rebound in oil prices and equities is on "risky ground" as there is still an air of uncertainty whether an agreement on a freeze to oil supply can be reached by oil producers in the Doha meeting on April 17.

On several occasions Iran has ruled itself out of a freeze to production as it looks to regain market share after international sanctions on it were lifted. Last week, Saudi Arabia's deputy crown prince, Mohammed bin Salman, signalled in an interview with Bloomberg that if any country raises output, Saudi Arabia will follow suit. But then earlier this week Kuwait's OPEC governor said the meeting will deliver a freeze in output.

"Oil prices continue to get excited by the April 17 Doha meeting despite a chance of a production freeze deal looking slim to say the least with Iran saying 'No' and Saudi Arabia saying 'Only with Iran'. Desire is there, but as in break-up speak 'it's complicated'," said Accendo Markets head of research Mike van Dulken.

At midday, Brent oil traded at USD40.69 a barrel, higher than the USD38.93 a barrel at the London stock market close on Thursday. US benchmark West Texas Intermediate was at USD38.52 a barrel, compared to USD36.84 a barrel late Thursday.

The rise in oil prices was supporting shares in oil producers. Royal Dutch Shell 'A', up 2.1% and BP, up 2.1%, were both amongst the best performers in the FTSE 100.

The blue-chip index itself was up 0.7%, or 43.45 points, to 6,180.34. The FTSE 250 was up 0.6% to 16,821.17 points, and the AIM All-Share was up 0.2% at 718.46.

In Europe, the French CAC 40 index was up 0.8% and the German DAX 30 was up 0.9%.

Ahead of the open on Wall Street, futures pointed the Dow 30 up 0.5%, the S&P 500 up 0.6% and the Nasdaq 100 up 0.7%.

UK stocks and the pound remained resilient in the face of declining UK industrial output. Figures from the Office for National Statistics showed industrial output fell 0.3% month-on-month in February from January when it grew 0.2% and was below expectations for growth of 0.1%.

Manufacturing output dropped 1.1% on a monthly basis reversing a 0.5% rise in January and bigger than a 0.2% fall forecast by economists.

Whilst the pound took a hit from the data,that still left it at a similar level to that at the London equities open: USD1.4052 versus USD1.4050.

Shares in consumer credit reference agency Experian, down 1.8%, and asset manager Schroders, down 1.1%, were both hit by broker downgrades. HSBC cut Experian to Reduce from Buy, and Exane BNP cut Schroders to Neutral from Outperform.

FTSE 250-listed Vectura Group was up 4.1%. The respiratory pharmaceuticals company and Jordan-founded drug maker Hikma Pharmaceuticals said the new drug application for their fluticasone propionate and salmeterol inhalation powder was accepted for filing by the Food & Drug Administration in the US.

The pair are working together on the inhalation powder, which is a generic version of GlaxoSmithKline's Advair Diskus, used to treat asthma and maintain treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease. Hikma shares were up 0.6%, while Glaxo shares were flat.

Elementis was the worst performer in the FTSE 250, down 8.1% after Berenberg downgraded the company to Hold from Buy, citing "a full-looking valuation" and the "potential reduction in pricing and margins" within Elementis’s chromium division.

DFS Furniture was down 5.0% to 305.00 pence after private equity firm Advent International Corp said it agreed to sell a 14.1% stake in the sofa retailer for GBP90.0 million.

Advent agreed to sell 30.0 million shares at 300.00p per share to institutional investors, leaving the private equity firm with a 24.1% stake in DFS, held through 51.4 million shares. Settlement of the accelerated bookbuild placing is expected to take place on Tuesday next week, Advent said in a statement.

Digital audio content services company Immedia Group said it signed a new five-year service contract with an undisclosed global brand to provide a supply of branded in-store music and marketing channels.

Under the deal Immedia will provide services to the brand's operations in the UK and Europe, and provide in-store equipment to facilitate delivery of the service, in return for an annual subscription fee per site.

Additionally, Immedia will produce language specific marketing content at contract prices, and will supply its Dreamstream decoder products to stores subscribing to the service. The company's share price more than doubled in response to the news.

Pathfinder Minerals was the worst performer in the AIM All-Share down 35%. The miner said a court in Mozambique made a ruling against the company in its lengthy litigation process. The company wants to appeal the decision as it continues to try to reclaim numerous licenses.

Pathfinder has been fighting over the ownership of Companhia Mineira de Naburi SARL, that hold the licenses. It claimed the rights to the licences were illegally seized by General Jacinto Veloso and Diogo Cavaco and was hoping the court would rule Pathfinder validly acquired a 99.99% stake in Companhia Mineira.

Veloso and Cavaco, for their part, claimed Pathfinder failed to pay the USD10.0 million required under the option agreement in place to buy the shares, meaning these licences could not have been seized as Pathfinder never owned them.

Still ahead in the economic calendar, the National Institute of Economic and Social Research's UK gross domestic product estimate is at 1500 BST, and the Baker Hughes US oil rig count is due at 1800 BST.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.